Allergy

Pharvaris To Present at the APAAACI 2023 International Conference

Retrieved on: 
Friday, October 13, 2023
HAE, Attack, International Conference on Learning Representations, ACIS, Asthma, Hereditary angioedema, Convention center, Conference, Pharmaceutical industry, Allergy

ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of an abstract oral presentation at the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) and Allergy and Clinical Immunology Society of Singapore (ACIS) APAAACI 2023 International Conference, to be held from October 23-26, 2023, at the Suntec Singapore International Convention and Exhibition Center in Singapore.

Key Points: 
  • ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of an abstract oral presentation at the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) and Allergy and Clinical Immunology Society of Singapore (ACIS) APAAACI 2023 International Conference, to be held from October 23-26, 2023, at the Suntec Singapore International Convention and Exhibition Center in Singapore.
  • Title: Bradykinin B2 receptor antagonist deucrictibant immediate-release capsule for treatment of HAE attacks: Phase 2 results
    Following the close of the session, the slide presentation will be made available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate ARS Pharmaceuticals, Inc. (SPRY) for Potential Violations of Securities Laws

Retrieved on: 
Thursday, October 12, 2023
Symantec Endpoint Protection, Law officers of the Crown, FDA, Food and Drug Administration, News, Vincent Wong, Food, CRL, Allergy, Adrenaline, Law, ARS, Pharmaceutical industry

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Attention ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) shareholders:

Key Points: 
  • NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Attention ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) shareholders:
    The Law Offices of Vincent Wong announce that an investigation has commenced into ARS and certain of its officers and directors regarding potential securities fraud.
  • The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.
  • In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions.
  • is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: SPRY)

Retrieved on: 
Wednesday, October 11, 2023
Symantec Endpoint Protection, FDA, Food and Drug Administration, News, Fraud, Food, CRL, Allergy, Adrenaline, ARS, Pharmaceutical industry

The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.

Key Points: 
  • The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.
  • In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions.
  • Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain ARS investors.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023

Retrieved on: 
Monday, October 9, 2023
CSU, Basophil, Antibody, Biology, Inflammation, Apoptosis, Risk, Rockefeller, KOL, Stanford University School of Medicine, Survival, FCR, Microbiology, B cell, Transplant, Patient, Stem cell factor, Infection, Therapy, Stanford Institutes of Medicine Summer Research Program, CD117, Fraunhofer Society, Berlin, Immunology, Immunity, S-1 Executive Committee, Hives, Syndrome, Pharmacology, SCF, Rockefeller University, FC, Executive Committee, Translational medicine, Vaccine, Pathology, Dermatology, Allergy, Jasper

Jasper’s leadership team will also provide an overview of upcoming clinical studies which will evaluate briquilimab’s potential as a therapeutic for both CSU patients and CIndU patients.

Key Points: 
  • Jasper’s leadership team will also provide an overview of upcoming clinical studies which will evaluate briquilimab’s potential as a therapeutic for both CSU patients and CIndU patients.
  • Briquilimab is an unconjugated aglycosylated anti-c-Kit antibody that blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF).
  • This mechanism of action disrupts the critical survival signal, leading to mast cell apoptosis thereby removing the underlying source of the inflammatory response in chronic urticaria.
  • He is also a member of the Executive Committee of the Stanford Institute for Immunity, Transplantation and Infection.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of ARS Pharmaceuticals, Inc.(SPRY)

Retrieved on: 
Monday, October 9, 2023
Symantec Endpoint Protection, Food, Telephone, Adrenaline, Food and Drug Administration, FDA, CRL, Levi, Allergy, News, ARS, Pharmaceutical industry

NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible violations of federal securities laws.
  • The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.
  • In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.

ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)

Retrieved on: 
Friday, October 6, 2023
Symantec Endpoint Protection, Food, Prescription, Adrenaline, Allergy, Risk, Caregiver, Food and Drug Administration, Absorption, Type, FDA, NDA, CRL, Committee, SAN, PD, Anaphylaxis, Patient, ARS, Pharmaceutical industry

The Type A meeting with FDA will be held by the end of October.

Key Points: 
  • The Type A meeting with FDA will be held by the end of October.
  • “Patients and caregivers are waiting for neffy to be approved and have expressed to us disappointment with the delay in the FDA approval.
  • We intend to work with FDA to meet the critical need for a needle-free epinephrine treatment as quickly as possible.
  • We are committed to meeting this urgent unmet medical need,” said Richard Lowenthal, Co-founder, President, and CEO of ARS Pharma.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: SPRY)

Retrieved on: 
Friday, October 6, 2023
Symantec Endpoint Protection, FDA, Food and Drug Administration, News, Fraud, Food, CRL, Allergy, Adrenaline, ARS, Pharmaceutical industry

The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.

Key Points: 
  • The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.
  • In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions.
  • Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain ARS investors.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of ARS Pharmaceuticals, Inc. (SPRY)

Retrieved on: 
Thursday, October 5, 2023
Symantec Endpoint Protection, Food, Telephone, Adrenaline, Food and Drug Administration, FDA, CRL, Levi, Allergy, News, ARS, Pharmaceutical industry

NEW YORK, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible violations of federal securities laws.
  • The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.
  • In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.

Global Royal Jelly Market Report 2023: Size, Market Share, Applications, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021-2031 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 16, 2023
Retail, Health, Agriculture, Natural Resources, Pharmaceutical, Vitamins, Supplements, Food, Beverage, Infection, Asthma, Obesity, Cholesterol, Anxiety, Prevalence, Hypotension, Wound healing, Nervous system, Growth, Allergy, Vitamin, Immune system, Acetylcholine, Dicarboxylic acid, Mineral, Infertility, Anaphylaxis, Drug, Food preservation, Marketing, Royal jelly

The "Royal Jelly Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Royal Jelly Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031" report has been added to ResearchAndMarkets.com's offering.
  • The global royal jelly market is experiencing significant demand driven by various factors.
  • What are the key micro and macro environmental factors that are impacting the growth of Royal Jelly market?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Royal Jelly market worldwide?

Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, YTE, HAE, Allergy, Atopic dermatitis, IND, Safety, Half-life, Therapy, OX40, Hereditary angioedema, Pathology, PD, AD, Investigational New Drug, Patient, Vaccine, Pharmaceutical industry, Asteria

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases.
  • Astria plans to develop the lead candidate, called STAR-0310, a monoclonal antibody OX40 antagonist that incorporates YTE half-life extension technology, for the treatment of AD.
  • Astria also sees an opportunity with STAR-0310 for potential expansion into additional indications.
  • Based on the inclusion of the YTE modification, Astria believes STAR-0310 has the potential to be dosed once every two to three months.